Breaking
Your Income Partners
Author

admin

Browsing
Politics

Federal judge strikes down Biden-era transgender regulation

A federal judge struck down a Biden-era rule that expanded federal anti-discrimination measures to transgender healthcare, writing that the Department of Health and Human Services (HHS) ‘exceeded its authority by implementing regulations redefining sex discrimination and prohibiting gender identity discrimination.’

The ruling from Judge Louis Guirola Jr. of the U.S. District Court for the Southern District of Mississippi came after a coalition of 15 Republican-led states sued over the matter, according to The Hill.

‘When Biden-era bureaucrats tried to illegally rewrite our laws to force radical gender ideology into every corner of American healthcare, Tennessee stood strong and stopped them,’ Tennessee Attorney General Jonathan Skrmetti said in a statement following the ruling. ‘Our fifteen-state coalition worked together to protect the right of healthcare providers across America to make decisions based on evidence, reason, and conscience.’

‘This decision restores not just common sense but also constitutional limits on federal overreach, and I am proud of the team of excellent attorneys who fought this through to the finish,’ he added.

Skrmetti’s office said the U.S. District Court for the Southern District of Mississippi held that HHS ‘exceeded its authority when it issued a rule in May 2024 redefining Title IX’s prohibition against discrimination ‘on the basis of sex’ — which Congress incorporated into the ACA through Section 1557 — to include gender identity.’

‘HHS’s 2024 rule represented a disturbing federal intrusion into the States’ traditional authority to regulate healthcare and make decisions about their own Medicaid programs. Specifically, the rule would have prohibited healthcare facilities from maintaining sex-segregated spaces, required certain healthcare providers to administer unproven and risky procedures for gender dysphoria, and forced states to subsidize those experimental treatments through their Medicaid programs,’ it continued. ‘In vacating the rule, Judge Louis Guirola determined that when Congress passed Title IX in 1972, ‘sex’ meant biological sex and that federal agencies cannot unilaterally rewrite laws decades later to advance political agendas.’

The states involved in the lawsuit were Tennessee, Mississippi, Alabama, Georgia, Indiana, Kansas, Kentucky, Louisiana, Nebraska, Ohio, Oklahoma, South Carolina, South Dakota, Virginia and West Virginia.

The rule was first created under the administration of former President Barack Obama in 2016, before President Donald Trump reversed it in his first term and then former President Joe Biden reversed it again, The Hill reported. 

Guirola’s ruling said HHS ‘exceeded its authority by implementing regulations redefining sex discrimination and prohibiting gender identity discrimination.’ 

The judge vacated the rule universally, but the rule had already been prevented from going into effect. It has been stayed since July 2024, according to Bloomberg Law. 

This post appeared first on FOX NEWS
Keep Reading
Investing

Canadian Investment Regulatory Organization Trade Resumption – QIM

Trading resumes in:

Company: Quimbaya Gold Inc.

CSE Symbol: QIM

All Issues: Yes

Resumption (ET): 8:15 AM

CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Canadian Investment Regulatory Organization (CIRO) – Halts/Resumptions

Cision View original content: http://www.newswire.ca/en/releases/archive/October2025/24/c1478.html

News Provided by Canada Newswire via QuoteMedia

This post appeared first on investingnews.com
Keep Reading
Politics

Federal judge strikes down Biden-era transgender regulations

A federal judge struck down a Biden-era rule that expanded federal anti-discrimination measures to transgender healthcare, writing that the Department of Health and Human Services (HHS) ‘exceeded its authority by implementing regulations redefining sex discrimination and prohibiting gender identity discrimination.’

The ruling from Judge Louis Guirola Jr. of the U.S. District Court for the Southern District of Mississippi came after a coalition of 15 Republican-led states sued over the matter, according to The Hill.

‘When Biden-era bureaucrats tried to illegally rewrite our laws to force radical gender ideology into every corner of American healthcare, Tennessee stood strong and stopped them,’ Tennessee Attorney General Jonathan Skrmetti said in a statement following the ruling. ‘Our fifteen-state coalition worked together to protect the right of healthcare providers across America to make decisions based on evidence, reason, and conscience.’

‘This decision restores not just common sense but also constitutional limits on federal overreach, and I am proud of the team of excellent attorneys who fought this through to the finish,’ he added.

Skrmetti’s office said the U.S. District Court for the Southern District of Mississippi held that HHS ‘exceeded its authority when it issued a rule in May 2024 redefining Title IX’s prohibition against discrimination ‘on the basis of sex’ — which Congress incorporated into the ACA through Section 1557 — to include gender identity.’

‘HHS’s 2024 rule represented a disturbing federal intrusion into the States’ traditional authority to regulate healthcare and make decisions about their own Medicaid programs. Specifically, the rule would have prohibited healthcare facilities from maintaining sex-segregated spaces, required certain healthcare providers to administer unproven and risky procedures for gender dysphoria, and forced states to subsidize those experimental treatments through their Medicaid programs,’ it continued. ‘In vacating the rule, Judge Louis Guirola determined that when Congress passed Title IX in 1972, ‘sex’ meant biological sex and that federal agencies cannot unilaterally rewrite laws decades later to advance political agendas.’

The states involved in the lawsuit were Tennessee, Mississippi, Alabama, Georgia, Indiana, Kansas, Kentucky, Louisiana, Nebraska, Ohio, Oklahoma, South Carolina, South Dakota, Virginia, and West Virginia.

The rule was first created under the administration of former President Barack Obama in 2016, before President Donald Trump reversed it in his first term and then former President Joe Biden reversed it again, The Hill reported. 

Guirola’s ruling said HHS ‘exceeded its authority by implementing regulations redefining sex discrimination and prohibiting gender identity discrimination.’ 

The judge vacated the rule universally, but the rule had already been prevented from going into effect. It has been stayed since July 2024, according to Bloomberg Law. 

This post appeared first on FOX NEWS
Keep Reading
Politics

Federal judges acknowledge court ruling errors tied to staffers’ AI use after Grassley inquiry

Two federal judges admitted that members of their staff used artificial intelligence to prepare court orders over the summer that contained errors.

The admissions, which came from U.S. District Judge Julien Xavier Neals in New Jersey and U.S. District Judge Henry Wingate in Mississippi, came in response to an inquiry by Sen. Chuck Grassley, R-Iowa, who chairs the Senate Judiciary Committee.

Grassley described the recent court orders as ‘error-ridden.’

In letters released by Grassley’s office on Thursday, the judges said the rulings in the cases, which were not connected, did not go through their chambers’ usual review processes before they were released.

The judges both said they have since adopted measures to improve how rulings are reviewed before they are posted.

Neals said in his letter that a June 30 draft decision in a securities lawsuit ‘was released in error – human error – and withdrawn as soon as it was brought to the attention of my chambers.’

The judge said a law school intern used OpenAI’s ChatGPT to perform legal research without authorization or disclosure that he also said was contrary to the chamber’s policy and relevant law school policy.

‘My chamber’s policy prohibits the use of GenAI in the legal research for, or drafting of, opinions or orders,’ Neals wrote. ‘In the past, my policy was communicated verbally to chamber’s staff, including interns. That is no longer the case. I now have a written unequivocal policy that applies to all law clerks and interns.’

Wingate said in his letter that a law clerk used Perplexity ‘as a foundational drafting assistant to synthesize publicly available information on the docket,’ adding that releasing the July 20 draft decision ‘was a lapse in human oversight.’

‘This was a mistake. I have taken steps in my chambers to ensure this mistake will not happen again,’ the judge wrote.

Wingate had removed and replaced the original order in the civil rights lawsuit, declining at the time to give an explanation but saying it contained ‘clerical errors.’

Grassley had requested that the judges explain whether AI was used in the decisions after lawyers in the respective cases raised concerns about factual inaccuracies and other serious errors.

‘Honesty is always the best policy. I commend Judges Wingate and Neals for acknowledging their mistakes and I’m glad to hear they’re working to make sure this doesn’t happen again,’ Grassley said in a statement.

‘Each federal judge, and the judiciary as an institution, has an obligation to ensure the use of generative AI does not violate litigants’ rights or prevent fair treatment under the law,’ the senator continued. ‘The judicial branch needs to develop more decisive, meaningful and permanent AI policies and guidelines. We can’t allow laziness, apathy or overreliance on artificial assistance to upend the Judiciary’s commitment to integrity and factual accuracy. As always, my oversight will continue.’

Lawyers have also faced scrutiny from judges across the country over accusations of AI misuse in court filings. In response, judges have issued fines or other sanctions in several cases over the past few years.

Reuters contributed to this report.

This post appeared first on FOX NEWS
Keep Reading
Business

Travis Kelce part of investor group aiming to revive struggling Six Flags

A group that includes activist investor Jana Partners and NFL player Travis Kelce says it has accumulated one of the largest ownership stakes in Six Flags Entertainment and intends to press the company’s leadership on ways to improve the struggling amusement park operator’s business.

Jana said Tuesday that the investor group now owns an economic interest of approximately 9% in Six Flags. The group plans to ‘engage’ with Six Flags’ management and board of directors to discuss ways to enhance shareholder value and improve visitors’ experience.

Shares in the Charlotte, North Carolina-based Six Flags surged 17.7% on the news. The shares added another 5.1% gain in after-hours trading. Even with Tuesday’s rally, the company’s shares are down about 47% so far this year.

Six Flags reported a loss of $319.4 million for the first half of the year. The company said attendance fell 9% in the three months that ended June 29, due partly to bad weather and a ‘challenged consumer’ in most of the markets it operates in.

The investor group also includes consumer executive Glenn Murphy and technology executive Dave Habiger.

Kelce, tight end for the Kansas City Chiefs, said in a statement that he grew up going to Six Flags amusement parks.

‘The chance to help make Six Flags special for the next generation is one I couldn’t pass up,’ he said.

This post appeared first on NBC NEWS
Keep Reading
Investing

Top 4 Canadian Biotech Stocks of 2025

Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.

Read on to learn what’s been driving these Canadian biotech firms.

1. Eupraxia Pharmaceuticals (TSX:EPRX)

Year-on-year gain: 141.23 percent
Market cap: C$410.85 million
Share price: C$8.25

Eupraxia Pharmaceuticals is developing clinical candidates that employ its DiffuSphere technology, which delivers treatments to the targeted tissues.

The company’s candidates are currently EP-104GI for eosinophilic esophagitis and EP-104IAR for knee osteoarthritis, and it is exploring the use of its technology for other active compounds as well.

Eupraxia added EP-104GI to its pipeline through its acquisition of EpiPharma Therapeutics in late 2023. The company has continued to advance the treatment through clinical trials in 2025 and released multiple rounds of positive data from its Phase 1b/2a trial cohorts.

In July, Eupraxia dosed its first patient after advancing its investigation to Phase 2b trials based on safety and efficacy data from the earlier Phase 2a patient cohorts. Top-line results from the Phase 2b study are anticipated in the second half of 2026.

In September, the company shared data from the highest-dose cohort of the still ongoing Phase 1b/2a trials, reporting that the group saw the largest improvements so far.

2. Bright Minds Biosciences (CSE:DRUG)

Year-on-year gain: 103.17 percent
Market cap: C$683.67 million
Share price: C$92.95

Bright Minds Biosciences is developing novel serotonin agonists targeting neurocircuit abnormalities linked to neuropsychiatric disorders and epilepsy, designing next-generation treatments that aim to retain the therapeutic benefits of psychedelics while minimizing side effects.

Its lead candidate, BMB-101, a selective 5-HT2C receptor agonist, has shown encouraging preclinical efficacy by stopping seizures in an epilepsy mouse model, evaluated jointly with Firefly Neuroscience (NASDAQ:AIFF).

The company’s stock surged nearly 1,500 percent in October 2024 following H. Lundbeck’s acquisition announcement of a competitor focused on similar targets. Strengthening its epilepsy expertise, Bright Minds expanded its scientific advisory board in early 2025 by adding five leaders in the field.

Ongoing clinical progress and strategic growth initiatives position Bright Minds as a promising contender in the neuropsychiatric treatment landscape.

3. Hemostemix (TSXV:HEM)

Year-on-year gain: 31.25 percent
Market cap: C$18.40 million
Share price: C$0.11

Hemostemix is a clinical-stage biotech company focused on developing autologous stem cell therapies, meaning the treatments use a patient’s own cells to theoretically enhance safety and efficacy.

Its main product, ACP-01, is an autologous cell therapy designed to promote tissue repair and regeneration in areas affected by diseases, including a range of heart diseases.

The company announced its first advanced sales orders for ACP-01 in Q1 2025 and has been working to expand internationally and attract new investment.

Hemostemix secured the regulatory green light for commercial sales in Florida after the state passed Senate Bill 1768. The bill creates a framework in which healthcare providers can administer stem cell therapies that had not yet been approved by the US Food and Drug Administration (FDA) but meet the bill’s guidelines.

The company now offers commercial ACP-01 treatments for ischemic pain in the state under the name VesCell, with sales forecasted to reach C$22.5 million in 2026. Operational plans target cash flow positivity by Q4 2026, supported by a growing physician network and commercial pipeline.

Additionally, Hemostemix is currently collaborating with Firefly Neuroscience on a Phase 1 clinical trial of ACP-01 for vascular dementia.

4. NervGen (TSXV:NGEN)

Year-on-year gain: 79.92 percent
Market cap: C$300.97 million
Share price: C$4.39

NervGen is a clinical-stage Canadian biotechnology company that focuses on developing innovative treatments to enable the nervous system to repair itself following damage from injury or disease.

The company’s core technology targets a mechanism that hinders nervous system repair. When the nervous system is damaged, chondroitin sulfate proteoglycans (CSPG) form a “scar.” Initially, CSPGs help contain damage, but their long-term interaction with the PTPσ receptor inhibits repair.

NervGen’s lead drug candidate, NVG-291, is designed to relieve these inhibitory effects to promote nervous system repair. It received fast-track designation from the US FDA.

NervGen is advancing NVG-291 in a Phase 1b/2a clinical trial for spinal cord injury (SCI) and reported positive data from the chronic cohort in June.

NVG-300, a newer preclinical candidate, is being evaluated for ischemic stroke and SCI.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com
Keep Reading
Investing

Quimbaya Gold Announces C$10 Million Bought Deal Financing

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES./

Quimbaya Gold Inc. (‘Quimbaya’ or the ‘Company’) (CSE: QIM,OTC:QIMGF) (OTCQB: QIMGF) (FSE: K05) is pleased to announce that it has entered into an agreement with Stifel Canada to act as sole underwriter and bookrunner (the ‘Underwriter’), in connection with a ‘bought deal’ private placement of 14,300,000 units of the Company  (the ‘LIFE Units’) at a price of C$0.70 per LIFE Unit (the ‘Offering Price’) for aggregate gross proceeds of C$10,010,000 (the ‘Offering’), with the LIFE Units to be issued pursuant to the Listed Issuer Financing Exemption (as defined below). 

The Company has granted to the Underwriter an option, exercisable up to 48 hours prior to the closing date, to purchase for resale up to an additional 15% of LIFE Units at the Offering Price for additional gross proceeds of up to C$1,501,500. 

Each LIFE Unit will consist of one common share (a ‘Common Share‘) and one-half (½) of one Common Share purchase warrant (each whole warrant, a ‘Warrant‘) of the Company. Each Warrant will be exercisable to acquire one Common Share for a period of 36 months following the closing date of the Offering at an exercise price of C$1.00 per common share.

The net proceeds from the Offering are expected to be used to advance the Company’s exploration programs, including drilling at the Tahami South project and follow-up work on regional copper-gold and gold targets, as well as for general working capital.

Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions (‘NI 45-106‘), the LIFE Units will be offered for sale to purchasers resident in Canada other than Quebec and/or other qualifying jurisdictions pursuant to the listed issuer financing exemption under Part 5A of NI 45-106 (the ‘Listed Issuer Financing Exemption‘). Because the Offering is being completed pursuant to the Listed Issuer Financing Exemption, the LIFE Units issued pursuant to the Offering will not be subject to a hold period pursuant to applicable Canadian securities laws. There is an offering document related to the Offering that can be accessed under the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and on the Company’s website at quimbayagold.com. Prospective investors should read the offering document before making an investment decision.

The Offering is scheduled to close on or about November 4, 2025 (the ‘Closing Date‘) and is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and other approvals including the acceptance of the Canadian Securities Exchange.

The securities referred to in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the ‘U.S. Securities Act‘), or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, ‘U.S. Persons’ (as such term is defined in Regulation S under the U.S. Securities Act) absent such registration or an applicable exemption from the registration requirements of the U.S. Securities Act. This news release does not constitute an offer for sale of securities for sale, nor a solicitation for offers to buy any securities. Any public offering of securities in the United States must be made by means of a prospectus containing detailed information about the company and management, as well as financial statements.

About Quimbaya 

Quimbaya aims to discover gold resources through exploration and acquisition of mining properties in the prolific gold mining districts of Colombia. Managed by an experienced team in the mining sector, Quimbaya is focused on three projects in the regions of Segovia (Tahami Project), Puerto Berrio (Berrio Project), and Abejorral (Maitamac Project), all located in Antioquia Province, Colombia.

Quimbaya Gold Inc.

Follow on X @quimbayagoldinc
Follow on LinkedIn @quimbayagold
Follow on YouTube @quimbayagoldinc
Follow on Instagram @quimbayagoldinc
Follow on Facebook @quimbayagoldinc

Cautionary Statements

Certain statements contained in this press release constitute ‘forward-looking information’ as that term is defined in applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. Generally, but not always, forward-looking statements and information can be identified by the use of forward-looking terminology such as ‘intends’, ‘expects’ or ‘anticipates’, or variations of such words and phrases or statements that certain actions, events or results ‘may’, ‘could’, ‘should’, ‘would’ or ‘occur’. Forward-looking statements herein include statements and information regarding the closing of the Offering, Offering’s intended use of proceeds, any exercise of Warrants, the future plans for the Company, including any expectations of growth or market momentum, future expectations for the gold sector generally, the Colombian gold sector more particularly, or how global or local market trends may affect the Company, intended exploration on any of the Company’s properties and any results thereof, the strength of the Company’s mineral property portfolio, the potential discovery and potential size of the discovery of minerals on any property of the Company’s, including Tahami South, the aims and goals of the Company, and other forward-looking information. Forward-looking information by its nature is based on assumptions and involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Quimbaya to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. These assumptions include, but are not limited to, that the Company’s exploration and other activities will proceed as expected. The future outcomes that relate to forward-looking statements may be influenced by many factors, including but not limited to: future planned development and other activities on the Company’s mineral properties; an inability to finance the Company; obtaining required permitting on the Company’s mineral properties in a timely manner; any adverse changes to the planned operations of the Company’s mineral properties; failure by the Company for any reason to undertake expected exploration programs; achieving and maintaining favourable relationships with local communities; mineral exploration results that are poorer or better than expected; prices for gold remaining as expected; currency exchange rates remaining as expected; availability of funds for the Company’s projects; prices for energy inputs, labour, materials, supplies and services (including transportation); no labour-related disruptions; no unplanned delays or interruptions in scheduled construction and production; all necessary permits, licenses and regulatory approvals are received in a timely manner; the Offering proceeds being received as anticipated; all requisite regulatory and stock exchange approvals for the Offering are obtained in a timely fashion; investor participation in the Offering; and the Company’s ability to comply with environmental, health and safety laws. Although Quimbaya’s management believes that the assumptions made and the expectations represented by such information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate. Furthermore, should one or more of the risks, uncertainties or other factors materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements or information. Readers are cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Quimbaya as of the date of this news release and, accordingly, is subject to change after such date. Except as required by law, Quimbaya does not expect to update forward-looking statements and information continually as conditions change.

SOURCE Quimbaya Gold Inc.

Cision View original content: http://www.newswire.ca/en/releases/archive/October2025/23/c7762.html

News Provided by Canada Newswire via QuoteMedia

This post appeared first on investingnews.com
Keep Reading
Business

Trump’s Argentina beef import plan will harm U.S. ranchers, industry warns

The American cattle ranching industry is blasting President Donald Trump’s proposal to purchase beef from Argentina in an effort to lower supermarket beef prices.

“This plan only creates chaos at a critical time of the year for American cattle producers, while doing nothing to lower grocery store prices,” Colin Woodall, CEO of the National Cattlemen’s Beef Association, said in a statement Monday.

Wyoming-based cattle operation Meriwether Farms addressed Trump directly in a social media post Monday.

“We love you and support you — but your suggestion to buy beef from Argentina to stabilize beef prices would be an absolute betrayal to the American cattle rancher,” the farm wrote on X.

By midday Tuesday, the post had already received 4 million views. A representative for Meriwether Farms did not immediately respond to a request for comment.

Trump floated purchasing beef from the South American nation Sunday aboard Air Force One to push down U.S. beef prices by increasing the overall supply.

‘We would buy some beef from Argentina,’ he told reporters, ‘If we do that, that will bring our beef prices down.’

Beef prices have hit record highs this year, according to data from the Bureau of Labor Statistics, fueled in part by depleted herd counts and steady demand from U.S. consumers.

This post appeared first on NBC NEWS
Keep Reading